Publisher Summary This chapter discusses clinical malaria vaccines. Vaccination of the
individual as well as vaccination of communities within endemic areas is discussed, as is the …

Malaria vaccine discovery and development follow two principal strategies. Most subunit
vaccines are designed to mimic naturally acquired immunity that develops over years upon …

The development of a vaccine against malaria has public health priority. In a controlled
setting, preliminary data on the efficacy of Plasmodium falciparum vaccine candidates can …

More than 30 years after the first report of successful vaccination against malaria using
radiation‐attenuated sporozoites, an effective malaria vaccine is not yet available. However …

Background Controlled human malaria infection (CHMI) by mosquito bite is a powerful tool
for evaluation of vaccines and drugs against Plasmodium falciparum malaria. However, only …

Reduction of transmission is important for effective malaria control. Standard microscopic
detection grossly underestimates the human transmission reservoir. Malaria transmission …

Although the malaria parasite was discovered more than 120 years ago, it is only during the
past 20 years, following the cloning of malaria genes, that we have been able to think …

Infection by malaria parasites (Plasmodium spp.) remains one of the leading causes of
morbidity and mortality, especially in tropical regions of the world. Despite the availability of …

Despite major efforts over the past 50 years to develop a malaria vaccine, no product has
been licensed yet. Irradiated sporozoites are the benchmark for an experimental live …

There is no licensed vaccine against any human parasitic disease and apicomplexan
parasites cause enormous human suffering; the malaria parasite alone kills approximately …